Related Experiment Video

Updated: Mar 28, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1

Claudia C S Chini1, Jair M Espindola-Netto2, Gourish Mondal1

  • 1Laboratory of Signal Transduction, Kogod Center on Aging, Mayo Clinic Cancer Center, Rochester, Minnesota. Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, Minnesota.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|December 15, 2015
PubMed
Abstract

Insights

SIRT1-activating compounds (STACs) show promise in treating pancreatic cancer by inhibiting cell growth and enhancing chemotherapy sensitivity. These compounds trigger a novel cell death pathway involving SIRT1 and lysosomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • SIRT1-activating compounds (STACs) are emerging as potential anticancer agents.
  • The precise mechanism of STACs in cancer therapy, particularly pancreatic cancer, requires further elucidation.

Purpose of the Study:

  • To investigate the therapeutic potential of STACs in pancreatic cancer.
  • To explore the underlying mechanisms by which STACs impact pancreatic cancer cells.

Main Methods:

  • In vitro studies using human pancreatic cancer cell lines.
  • In vivo xenograft experiments in mouse models.
  • Mechanistic studies to identify cell death pathways.

Main Results:

  • SIRT1 is upregulated in pancreatic cancer cells.
  • STACs (SRT1720, SRT1460, SRT3025) significantly inhibited pancreatic cancer cell growth and survival.
  • STACs potentiated the efficacy of gemcitabine and paclitaxel, suggesting combination therapy potential.
  • STACs demonstrated potent inhibition of tumor xenograft growth.
  • STACs induced a SIRT1 lysosomal-dependent cell death pathway, influenced by DBC1 expression.

Conclusions:

  • SIRT1 and lysosomes play a critical role in the STAC-regulated cell death pathway in pancreatic cancer.
  • STACs represent a promising therapeutic strategy for pancreatic cancer, potentially in combination with existing chemotherapies.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
4.6K